Jul, 17 2019 09:20 JST
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
TOKYO, Jul, 17 2019 - (JCN Newswire) - Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate) for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane, from the China National Medical Products Administration (NMPA).
This approval is based on the results of Study 304,(1) which was a multicenter, open-label, randomized, parallel group Phase III clinical study, to evaluate the efficacy and safety of Halaven and vinorelbine in 530 women with locally recurrent or metastatic breast cancer, previously treated with chemotherapy regimens, including an anthracycline and a taxane. Halaven demonstrated a statistically significant extension in the study's primary endpoint of progression-free survival (PFS) over the comparator treatment vinorelbine according to independent imaging review (Hazard Ratio: 0.80; 95% Confidence Interval: 0.65-0.98; p = 0.036).
The five most common adverse events observed in the Halaven arm of this study were white blood cell count decreased, neutrophil count decreased, increased aspartate aminotransferase, increased alanine aminotransferase, and anemia, which is consistent with the known side-effect profile of Halaven.
The number of women diagnosed with breast cancer in China has increased in recent years,(2) with an estimated 368,000 new cases of breast cancer and approximately 98,000 related deaths in 2018.3 Breast cancer is now the most frequently diagnosed cancer in Chinese women.(3)
Halaven is a halichondrin class microtubule dynamics inhibitor with a distinct binding profile. In addition to its mechanism of action of inhibiting the growth of microtubule dynamics, non-clinical studies showed Halaven's unique actions on the tumor microenvironment such as an increase in vascular perfusion and permeability in tumor cores,(4) promotion of the epithelial state, decrease in the capacity of breast cancer cells to migrate,(5) etc. For use in the treatment of breast cancer, Halaven is currently approved in over 65 countries worldwide, including the United States, Japan and countries in Europe and Asia.
Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. Lenvima has been available as a treatment of patients with unresectable hepatocellular carcinoma who have not received prior systematic therapy in China since November 2018. With this approval of Halaven, Eisai seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers in China.
(1) Yuan P et al., Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomized clinical trial Eur J Cancer, 2019; 112, 57-65
(2) Lei F et al., Breast cancer in China. The Lancet Oncology, 2014; 15(7), e279'e289
(3) Ferlay J, et al., (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. https://gco.iarc.fr/today(New Window), As of July 17, 2019
(4) Funahashi Y et al., Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models. Cancer Sci., 2014; 105, 1334-1342
(5) Yoshida T et al., Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states. Br J Cancer, 2014; 110, 1497-1505
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Neurology and Oncology.
In its medium-term business plan EWAY2025, Eisai is aiming to become a "Medico Societal Innovator" (a company that changes society through creating medicines and providing solutions), and is working on establishment of ecosystem platform business utilizing various data such as a large amount of clinical data, experiences, and know-how.
For more information about Eisai Co., Ltd., please visit https://www.eisai.co.jp.
Public Relations Department,
Eisai Co., Ltd.
Copyright ©2020 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
More Latest Release >>
DOCOMO to Partner with AI-powered Enterprise Meeting Note Provider Otter.ai in Japan
Jan 22, 2020 12:21 JST
DOCOMO to Pursue Collaboration with Skydio, U.S. Manufacturer of Autonomous Drones Capable of Flying without GPS Guidance
Jan 22, 2020 12:00 JST
Mitsubishi Motors concludes a disaster cooperation agreement for the first time in Tokyo with Minato City
Jan 21, 2020 20:04 JST
DOCOMO and DOCOMO ASIA to Provide IoT Solution for YANMAR's SMARTASSIST System in India
Jan 21, 2020 16:13 JST
NEC Highlights 5G-enabled Business Creation and Connectivity at MWC Barcelona 2020
Jan 20, 2020 16:08 JST
Eisai Rated "A", the Highest Rating in the CDP Climate Change Report 2019
Jan 20, 2020 15:21 JST
Fujitsu Group Earns Top Rating in CDP Climate Change Evaluation for Third Year Running
Jan 20, 2020 15:03 JST
Showa Denko to Streamline Domestic Production of Unsaturated Polyester Resin and Vinyl Ester Resin
Jan 20, 2020 12:30 JST
Toyota Indiana Completes $1.3 Billion Modernization Project; Includes 550 New Jobs
Jan 20, 2020 08:46 JST
Toyota Yaris WRC Trio Start a New Chapter with a Classic Challenge
Jan 17, 2020 20:05 JST
DOCOMO Conducts World's First Successful Trial of Transparent Dynamic Metasurface
Jan 17, 2020 16:05 JST
Hitachi Industrial Products Received "EN 15085 Certificate" for Welding of Railway Vehicles and Components
Jan 17, 2020 13:45 JST
Hitachi Completes Construction of H1 TOWER, One of World's Tallest Elevator Test Towers, at R&D and Manufacturing Facility in Guangzhou, China
Jan 17, 2020 09:33 JST
Hitachi Joined WIPO GREEN as a Contributing Partner
Jan 17, 2020 09:07 JST
Fujitsu and Upstream Security Partner for Vehicle Security
Jan 16, 2020 15:23 JST
Toyota to Gradually Expand Service Area of "my route", the Multi-Modal Mobility Service
Jan 16, 2020 13:08 JST
Toyota and Joby Aviation are Flying to New Heights Together
Jan 16, 2020 09:06 JST
Isuzu and Honda Sign an Agreement to Conduct Joint Research on Fuel Cell-powered Heavy-duty Trucks
Jan 15, 2020 15:27 JST
NEC Qualifies 20 Fiber Pair Subsea Telecom Cable Systems, with Further Advances Soon
Jan 15, 2020 12:00 JST
NEC Concludes an Advisory Agreement with Former NGA Director Robert Cardillo
Jan 14, 2020 17:00 JST